CHRS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Coherus Oncology Inc (CHRS) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company shows promising growth in revenue and gross margin, its financials remain negative with a significant net loss. Technical indicators do not suggest a clear upward trend, and there are no strong trading signals or recent positive news catalysts to support immediate investment.
The MACD is negative and contracting, RSI is neutral at 40.378, and moving averages are converging, indicating no clear trend. The stock is trading below the pivot level of 1.779, with key support at 1.591 and resistance at 1.966. Overall, the technical indicators suggest a neutral to slightly bearish outlook.
Revenue increased by 91.19% YoY, gross margin improved to 67.84%, and analysts have initiated coverage with an Outperform rating and a $10 price target, citing promising clinical developments.
Technical indicators are neutral to bearish, and there are no significant trading trends or recent news to drive momentum.
In Q3 2025, revenue increased significantly by 91.19% YoY to $11.57M, and gross margin improved to 67.84%. However, the company reported a net loss of -$35.53M, though this is an improvement of 230.49% YoY. EPS also improved to -0.31, up 244.44% YoY.
Oppenheimer initiated coverage with an Outperform rating and a $10 price target, citing upcoming clinical readouts and a high-potential early-stage opportunity with its anti-IL-27 antibody.
